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ABSTRACT
A challenge in precision medicine requires identification of
actionable driver mutations. Critical to such effort is the deploy-
ment of sensitive and well-validated assays for mutation detec-
tion. Although identification of such alterations within the
tumor tissue remains the gold standard, many advanced non-
small cell lung cancer cases have only limited tissue samples,
derived from small biopsies or fine-needle aspirates, available
for testing. More recently, noninvasive methods using either cir-
culating tumor cells or tumor DNA (ctDNA) have become an
alternative method for identifying molecular biomarkers and
screening patients eligible for targeted therapies. In this
article, we present a case of a 52-year-old never-smoking
male who presented with widely metastatic atypical neuro-
endocrine tumor to the bones and the brain. Molecular
genotyping using DNA harvested from a bone metastasis
was unsuccessful due to limited material. Subsequent ctDNA
analysis revealed an ALK translocation. The clinical signifi-
cance of the mutation in this particular cancer type and
therapeutic strategies are discussed. The Oncologist 2017;22:
768–773
KEY POINTS
 To our knowledge, this index case represents the first reported ALK translocation identified in an atypical carcinoid tumor.
 Liquid biopsy such as circulating tumor DNA is a feasible alternative platform for identifying sensitizing genomic alterations.
 Second-generation ALK inhibitors represent a new paradigm for treating ALK-positive patients with brain metastases.
PATIENT STORY
A 52-year-old never-smoking male initially presented with
acute-on-chronic back pain, which gradually worsened to
involve the hips and shoulders. After several months of con-
servative management without relief, lumbar spine magnetic
resonance imaging (MRI) showed multifocal abnormal mar-
row enhancement suggesting an infiltrative process. Bone
scan showed abnormal uptake throughout the axial skeleton,
including the skull, sternum, bilateral ribs, and the sacroiliac
joints. Computed tomography (CT) of the chest, abdomen,
and pelvis identified a large spiculated mass in the right mid-
dle lobe of the lung spanning 1.2 3 1.0 cm and a lytic lesion
in the manubrium. Brain MRI revealed a 4.3-cm mass to the
right of the falx cerebri with extensive calcifications and vaso-
genic edema, a rim-enhancing lesion in the posterior aspect
of the left superior frontal gyrus, and numerous punctate foci
of enhancement infra- and supra-tentorially and within the
calvarium (Fig. 1A). The patient complained of floaters, and
fundoscopic examination showed bilateral choroidal metas-
tases (Fig. 1B).
CT-guided, fine-needle aspiration of the manubrium lesion
and the right middle lobe lesion both revealed monomorphic
tumor cells with moderate amount of eosinophilic cytoplasm,
forming organoid nests with small foci of coagulative necrosis,
that stained diffusely positive for TTF-1, CK7, synaptophysin,
and neural-specific enolase and focally positive for chromo-
granin. High-grade features were not identified in this speci-
men. Ki67 was approximately 30%. These cells were negative
for CK5/6 and p40. The morphological appearance, positive
neuroendocrine markers, and intermediate Ki67 all suggest a
neuroendocrine tumor of the atypical carcinoid subtype assum-
ing lung origin (Fig. 2). Molecular genotyping could not be com-
pleted due to insufficient material.
Planned gamma knife radiotherapy was aborted due to
innumerable brain metastases. Because the patient was
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Figure 1. Regression of brain and choroidal metastases after alectinib. (A): T1 gadolinium enhanced MRI images npre- and post-treatment
showing shrinkage of the dominant brain lesion. (B): Right fundus at presentation with a small metastasis in the temporal macula. (C):
Left fundus with tumors inferior to the optic disc and in the temporal macula. (D): Right fundus 2 months later with tumor regression. (E):
Left fundus 2 months later with regression of the juxtapapillary tumor and disappearance of the temporal metastasis. Ultrasound scans
showing left juxtapapillary tumor at presentation, when the thickness was 1.3 mm (F), and after 2 months, when the thickness had dimin-
ished to 0.5 mm (G). The metastases are indicated by red arrows.
Abbreviations: MRI, magnetic resonance imaging.
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minimally symptomatic neurologically, whole brain radiation
was deferred. Systemic therapy with temozolamide and capeci-
tabine was initiated, with dexamethasone added to control cer-
ebral edema. Restaging scans after two cycles showed stable
bone disease but worsening brain metastases. At that time, the
patient was referred to our clinic and a hybrid capture-based cir-
culating tumor DNA (ctDNA) test (FoundationACT, Foundation
Medicine, Cambridge, MA, http://www.foundationone.com)
revealed an ALK translocation.
MOLECULAR TUMOR BOARD
The Expanding Role of Liquid Biopsies
Liquid biopsies utilizing ctDNA offer an alternate means of
detecting genomic alterations to inform treatment. Compared
with traditional tissue biopsies, liquid biopsies are faster, more
economical, and less invasive, thereby reducing the health risk
to patients. Liquid biopsies are most useful when a patient’s
clinical condition precludes a tissue diagnosis or the lesion in
question is anatomically inaccessible. Because tissue biopsies
usually sample only a small portion of the tumor, mutations
may be missed due to tumor heterogeneity. Liquid biopsies
have the potential to sample all metastatic sites, to monitor
therapeutic response, and to predict recurrences through serial
sampling. Finally, because ctDNA samples do not undergo for-
malin fixation, background is reduced.
The greatest challenge of liquid biopsies is the false nega-
tive rates. Although several series report mutation detection
rates between 60%–80% for ctDNA, some cancers may simply
shed little DNA into circulation because of small size, limited
metastatic spread, or other factors [1]. Liquid biopsies may
miss co-occurring mutations and tumors with mixed histology.
GENOTYPING RESULTS AND INTERPRETATION OF THE
MOLECULAR RESULTS
Molecular profiling was performed in a Clinical Laboratory
Improvement Amendments-certified laboratory using a hybrid
capture ctDNA platform. Briefly, 10–20 mL peripheral, whole
blood was collected from the patient and spun down to collect
5–10 mL of plasma. Greater than 50 ng of ctDNA was extracted
from the sample and quantitated using smear analysis. An
adaptor-ligation library was constructed and hybrid capture
was performed using a panel of 2,695 50 biotinylated single-
stranded DNA oligonucleotides to isolate exonic regions of 62
genes and introns of six genes often involved in genomic rear-
rangement in cancer. A sequencing library was prepared with
short oligonucleotide sequences called fragment-barcodes
inserted between the sequencing adaptor and the sample bar-
code that allow downstream analysis to uniquely identify the
original double-stranded DNA fragment. Multiplexed sequenc-
ing was performed using 2 3 175 paired-end on the Illumina
HiSeq 2500 platform (Illumina, San Diego, CA, https://www.illu-
mina.com). Analyses included error correction across duplicate
ctDNA molecules, as identified by the fragment barcodes, to
<0.02% and target depth post-correction of >5,0003 unique
coverage. Variant calling included indels, substitutions, rear-
rangements, and amplifications. Reporting of ctDNA was done
without a matched normal sample from the patient and com-
pared with known driver alterations in the Catalogue of
Somatic Mutations in Cancer (COSMIC) database.
ctDNA allows for sampling across all metastatic sites. ctDNA
from this patient detected only two mutations: the ALK translo-
cation and a variant in the PDCD1LG2 gene of unknown signifi-
cance. The ALK rearrangement in this patient occurred at the
canonical intron 19 breakpoint and contained the kinase
domain of ALK. This event was a translocation between chro-
mosome 2 and chromosome 9 leading to an out-of-strand rear-
rangement with SMC5 intron 18 where the SMC5 gene was in
the opposite transcriptional orientation as ALK (Fig. 3). The
median exon coverage for this sample was 5,986. Even though,
to our knowledge, ALK translocations have not been reported
previously in atypical carcinoid cancer, and SMC5 has never
been identified as a fusion partner for ALK, we hypothesized
that this fusion was likely the driver mutation because it con-
tained an intact kinase domain capable of downstream signal-
ing. Although we could not rule out the presence of a subclonal
population harboring other driver mutations, given the paucity
of mutations identified, we believe the patient’s tumor was rel-
atively homogeneous and the ALK rearrangement represented
a truncal mutation that disseminated early during evolution.
Because ctDNA is a new platform, the sensitivity and specificity
of the test remains uncertain. Extrapolating from a prior report
using circulating tumor cells, investigators were able to identify
ALK translocation with 100% sensitivity and specificity [2].
Figure 2. Core biopsy findings. (A): Hematoxylin and eosin section
shows consolidated lung parenchyma with invasive nests of neo-
plastic epithelioid cells within a surrounding desmoplastic stroma.
The tumor cells have round-to-ovoid nuclei with dense chromatin,
rare small nucleoli, and moderate amount of eosinophilic cyto-
plasm. Adjacent normal lung parenchyma is seen on the left
(3200). (B): Immunohistochemical stain for synaptophysin dem-
onstrates positive cytoplasmic granular staining (3400).
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Furthermore, not all tumors shed DNA into the blood stream.
Therefore, we would surmise that the actual false negative rate
for detecting ALK translocation would be higher than the false
positive rate. Being able to detect the translocation at all in the
blood sample suggests it was likely an actionable driver muta-
tion in this patient.
FUNCTIONAL AND CLINICAL SIGNIFICANCE OF THE ALK
MUTATION
ALK encodes the anaplastic lymphoma kinase, a receptor tyro-
sine kinase that belongs to the insulin receptor superfamily and
induces downstream activation of pathways associated with
cell survival, angiogenesis, and proliferation [3]. It was first iden-
tified as a fusion with the echinoderm microtubule-associated
protein-like 4 (EML4) gene in lung cancer in 2007, and this
fusion is sufficient to transform 3T3 cells in vitro and induce
tumor formation in nude mice in vivo [4]. Since then, other
fusion partners have been identified with ALK, including TFG
and KIF5B [5, 6]. The rearrangement in this tumor has a break-
point within ALK intron 19, resulting in separation of the ALK
kinase domain (exons 20–29) from the N-terminal regions
(exons 1–19). When expressed in cultured cells, the kinase
domain of ALK exhibits oncogenic activity [7, 8].We hypothesize
the fusion in this patient’s tumor to be oncogenic because it
contains the intact ALK kinase domain. Clinically the EML4-ALK
gene fusion has been observed in 3%–7% of non-small cell
lung cancer (NSCLC) cases, and these patients tend to be
younger, non-smoking males of Asian heritage [9]. Notably,
ALK mutation has not been observed in 12 atypical lung
carcinoid-endocrine samples analyzed in the COSMIC database
to date.
POTENTIAL STRATEGIES TO TARGET THE PATHWAYAND
IMPLICATIONS FOR CLINICAL PRACTICE
The ALK inhibitors crizotinib, ceritinib, and alectinib have been
approved for the treatment of patients with metastatic NSCLC
whose tumors test positive for ALK rearrangement [10–14].
Several others, such as brigatinib and lorlatinib, are currently in
preclinical studies [15, 16]. The first-generation ALK inhibitor
crizotinib is the preferred initial therapy for patients whose
tumor harbors the ALK fusion because results of a phase III trial
comparing crizotinib with chemotherapy demonstrated
improved progression-free survival (PFS), response rates (RR),
and quality of life [17]. The incidence of brain metastases in
newly diagnosed stage IV ALK-positive NSCLC is approximately
20%–30%, comparable to those without the ALK fusion [17,
Figure 3. Novel ALK fusion. (A): Circulating tumor DNA sequencing revealed an ALK intron 19 translocation with an out-of-strand fusion to
SMC5 gene. (B): Integrated Genomic Viewer alignment with a median exon coverage of6,000. Breakpoint denoted in color.
Table 1. Treatment options
ALK inhibitor Generation Responses in patients with CNS disease
Crizotinib First; FDA approved PROFILE 1014 [18]: ORR 30/39 (77%) with crizotinib;
11/40 (28%) with chemotherapy
Alectinib Second; FDA approved J-ALEX [26]: 1 event/14 with alectinib;
16 events/29 with crizotinib;
PFS HR 0.08 favoring alectinib (CI95 0.01–0.61)
Ceritinib Second; FDA approved ASCEND-4 [31]: IC-ORR 25/54 (46.3%) with ceritinib;
11/52 (21.2%) with chemotherapy
Brigatinib Phase II ALTA [30]: IC-ORR 36% 90 mg daily and 67% 180 mg
Loralatinib Phase II 10/32 (31%) [29]
Abbreviations: CNS, central nervous system; FDA, Food and Drug Administration; IC-ORR, intracranial overall response rate; PFS HR, progression
free survival hazard ratio; ORR, overall response rate.
Wang, Young, Ali et al. 771
www.TheOncologist.com Oc AlphaMed Press 2017
18].With improved control of systemic disease using crizotinib,
however, approximately 60% of patients will ultimately develop
brain metastases [19–21]. This observation is in part due to the
poor central nervous system (CNS) penetration of crizotinib
[22]. Until recently, surgery and/or radiation have been the
mainstay of treatment for patients with brain metastases,
including those with ALK fusions, although next-generation ALK
inhibitors may alter this treatment paradigm because of their
impressive intracranial activity (Table 1). A small phase I/II trial
of alectinib consisting of 21 crizotinib-refractory patients
showed a complete response in 29% (6), partial response in
24% (5), stable disease in 38% (8), and progression only in 10%
(2) [23]. In a subsequent phase II study, objective responses
were observed in 67% of the patients (10 complete responses
and two partial responses) with baseline brain metastases who
had not received prior CNS directed treatment, 28% with stable
disease, and only 6% (1 patient) with CNS progression [13].
Similarly, other second-generation ALK inhibitors, certinib and
brigatinib, have demonstrated intracranial overall RR between
36% to 63% in early phase studies, depending on whether the
patient has had prior exposure to an ALK inhibitor [24, 25]. A
recent interim analysis of the phase III J-ALEX trial, where 207
treatment-na€ıve, Japanese, ALK-positive patients were random-
ized either to receive alectinib or crizotinib in the first-line set-
ting, showed improved PFS and tolerability with alectinib. The
median PFS for crizotinib was 10.2 months (HR 0.34, 99% CI
0.17–0.7, p< .0001) but the PFS has not been reached in the
alectinib arm [26]. A global phase III study comparing crizotinib
with alectininb in the upfront setting (ALEX) has finished
accrual with results expected next year. In this case of NSCLC
with diffuse CNS disease and a suspected oncogenic ALK trans-
location, the molecular tumor board recommended initiating
therapy with the second-generation ALK inhibitor alectinib.
Patient Update
In the case of this 52-year-old man with newly diagnosed meta-
static ALK-positive atypical carcinoid tumor, the patient was
started on alectinib with rapid shrinkage of his disease after 1
month, notably the brain and choroidal metastases (Fig. 2). He
achieved a partial response with approximately 60% shrinkage
of his dominant brain metastatic lesion and resolution of many
smaller lesions. All the choroidal lesions resolved. The impres-
sive clinical response supports that the novel ALK translocation
identified using ctDNA is the driver mutation in this patient’s
tumor. His disease remains stable after 5 months and the
patient continues on alectinib.
CONCLUSION
Given the dramatic response to alectinib, the question was
raised whether to pursue stereotactic radiation to the
remaining brain lesions. Evidence on this topic is limited,
although case reports have shown an increased risk of radio-
necrosis with alectinib [27]. Therefore, we recommended
expectant management with close surveillance. At progression,
efforts will be made to identify resistance mechanisms via
direct biopsy of accessible sites of progression or by utilization
of ctDNA. Treatment options directed at CNS progression
include alectinib dose escalation (from 600 mg p.o. b.i.d to
900 mg p.o. b.i.d) to re-induce CNS response versus the third-
generation ALK inhibitor lorlatinib, which has shown high CNS
penetration and response in a heavily pre-treated patient
cohort [28, 29]. Therapies for systemic progression include
chemotherapy such as platinum and pemetrexed combination
versus lorlatinib.
GLOSSARY OF GENOMIC TERMS AND NOMENCLATURE
Circulating tumor cells: tumor cells identified circulating in the patient’s blood
thought to be derived from tumor shedding
Circulating tumor DNA: tumor DNA identified in the patient’s blood thought to
be released upon tumor cell death
Hybrid capture-based comprehensive genomic profiling: method of
sequencing DNA using probes to pull down exons and fusions of interest
Indel: insertions or deletions of bases in the DNA
Median exon coverage: average number of times an exon is read during
sequencing
Pair-end sequencing: sequencing from both ends of a DNA as opposed to just
from one end (single-end)
Substitution: a DNA mutation that exchanges one base for another
Target depth correction: an error-correction process where fragment barcodes
are employed to identify polymerase chain reaction duplicates of unique
ctDNAmolecules and merge them into a single consensus read
Translocation or rearrangement: a chromosome abnormality whereby parts of
non-homologous chromosomes join together
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Editor’s Note: See the related commentary, “ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the
Haystack,” by Meghan J. Mooradian and Justin F. Gainor on pages 759–761 of this issue.
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